AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer's disease mouse model

• Published in: bioRxiv
• Main Authors: Rincon, Melvin, Zhou, Lujia, Marneffe, Catherine, Voytyuk, Iryna, Wouters, Yessica, Dewilde, Maarten, Duqué, Sandra I, Vincke, Cécile, Levites, Yona, Golde, Todd E, Muyldermans, Serge, De Strooper, Bart, Holt, Matthew G
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 13.07.2019
• Subjects: Alzheimer's disease; Amyloidosis; Central nervous system; Expression vectors; Gene transfer; Nanobodies; Neurodegenerative diseases; Neurological diseases; Parenchyma; β-Site APP-cleaving enzyme 1
• DOI: 10.1101/698506

Single domain antibodies (VHH) are potentially disruptive therapeutics, with important biological value for the treatment of several diseases, including neurological disorders. However, VHH have not been widely used in the central nervous system (CNS), as it is hard to reach therapeutic levels, both because of their restricted blood-brain-barrier penetration and their apparent rapid clearance from the parenchyma. Here, we propose a gene transfer strategy based on adeno-associated virus (AAV)-based vectors to deliver VHH directly into the CNS, ensuring continuous production at therapeutic levels. As a proof-of-concept, we explored the potential of AAV-delivered VHH to inhibit BACE1, a well-characterized target in Alzheimer′s disease. First, we generated a panel of VHHs targeting BACE1. One of them, VHH-B9, showed high selectivity for BACE1 and efficacy in lowering BACE1 activity in vitro. We then went on to demonstrate significant reductions in amyloid-beta (Aβ) levels after AAV-based delivery of VHH-B9 into the CNS of a mouse model of cerebral amyloidosis. These results constitute a novel therapeutic approach for neurodegenerative diseases, which is applicable to a range of CNS disease targets.